Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants

Javier T. Varona-Santos, Roberto I Vazquez-Padron, Leticia Moreno-Fierros

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Synthetic peptides have been shown to evoke neutralizing and cytotoxic protective anti-HIV responses in mice and other animal models. Recent data support that C4V3 peptides can induce anti-V3 antibodies that neutralize primary isolates. Critical to the success of peptide-based vaccines is the development of strategies to augment their immunogenicity while reducing their large-scale production costs. Therefore, finding efficient and economical alternatives for the production of epitopic vaccines could have an impact on researches using such immunogens. Herein, we report the recombinant production and immunological characterization of a short polypeptide which carries the three relevant epitopes contained in a C4V3 peptide. This polypeptide, named rC4V3, was efficiently produced in E. coli, yielding more than 75 mg per culture liter. No major difficulties were found in the recovery, refolding and purification of this peptide; the latter facilitated by C-terminal inclusion of a histidine tag. The immunogenicity of this protein was studied by administering it intramuscularly or intranasally to mice and it demonstrated to be a strong elicitor of anti-HIV antibodies at systemic and mucosal compartments. Remarkably, such responses were attained with rC4V3 even without the need of adjuvants. We can conclude that this protein might be a promising tool for studies using epitope-based vaccine designs.

Original languageEnglish
Pages (from-to)237-249
Number of pages13
JournalViral Immunology
Volume19
Issue number2
DOIs
StatePublished - Jul 19 2006

Fingerprint

HIV-1
HIV
Peptides
Epitopes
Anti-Idiotypic Antibodies
Vaccines
HIV Antibodies
Subunit Vaccines
Histidine
Proteins
Animal Models
Escherichia coli
Costs and Cost Analysis
Research

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants. / Varona-Santos, Javier T.; Vazquez-Padron, Roberto I; Moreno-Fierros, Leticia.

In: Viral Immunology, Vol. 19, No. 2, 19.07.2006, p. 237-249.

Research output: Contribution to journalArticle

@article{c166e932a4bf4e96bc2ed0077f627bed,
title = "Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants",
abstract = "Synthetic peptides have been shown to evoke neutralizing and cytotoxic protective anti-HIV responses in mice and other animal models. Recent data support that C4V3 peptides can induce anti-V3 antibodies that neutralize primary isolates. Critical to the success of peptide-based vaccines is the development of strategies to augment their immunogenicity while reducing their large-scale production costs. Therefore, finding efficient and economical alternatives for the production of epitopic vaccines could have an impact on researches using such immunogens. Herein, we report the recombinant production and immunological characterization of a short polypeptide which carries the three relevant epitopes contained in a C4V3 peptide. This polypeptide, named rC4V3, was efficiently produced in E. coli, yielding more than 75 mg per culture liter. No major difficulties were found in the recovery, refolding and purification of this peptide; the latter facilitated by C-terminal inclusion of a histidine tag. The immunogenicity of this protein was studied by administering it intramuscularly or intranasally to mice and it demonstrated to be a strong elicitor of anti-HIV antibodies at systemic and mucosal compartments. Remarkably, such responses were attained with rC4V3 even without the need of adjuvants. We can conclude that this protein might be a promising tool for studies using epitope-based vaccine designs.",
author = "Varona-Santos, {Javier T.} and Vazquez-Padron, {Roberto I} and Leticia Moreno-Fierros",
year = "2006",
month = "7",
day = "19",
doi = "10.1089/vim.2006.19.237",
language = "English",
volume = "19",
pages = "237--249",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants

AU - Varona-Santos, Javier T.

AU - Vazquez-Padron, Roberto I

AU - Moreno-Fierros, Leticia

PY - 2006/7/19

Y1 - 2006/7/19

N2 - Synthetic peptides have been shown to evoke neutralizing and cytotoxic protective anti-HIV responses in mice and other animal models. Recent data support that C4V3 peptides can induce anti-V3 antibodies that neutralize primary isolates. Critical to the success of peptide-based vaccines is the development of strategies to augment their immunogenicity while reducing their large-scale production costs. Therefore, finding efficient and economical alternatives for the production of epitopic vaccines could have an impact on researches using such immunogens. Herein, we report the recombinant production and immunological characterization of a short polypeptide which carries the three relevant epitopes contained in a C4V3 peptide. This polypeptide, named rC4V3, was efficiently produced in E. coli, yielding more than 75 mg per culture liter. No major difficulties were found in the recovery, refolding and purification of this peptide; the latter facilitated by C-terminal inclusion of a histidine tag. The immunogenicity of this protein was studied by administering it intramuscularly or intranasally to mice and it demonstrated to be a strong elicitor of anti-HIV antibodies at systemic and mucosal compartments. Remarkably, such responses were attained with rC4V3 even without the need of adjuvants. We can conclude that this protein might be a promising tool for studies using epitope-based vaccine designs.

AB - Synthetic peptides have been shown to evoke neutralizing and cytotoxic protective anti-HIV responses in mice and other animal models. Recent data support that C4V3 peptides can induce anti-V3 antibodies that neutralize primary isolates. Critical to the success of peptide-based vaccines is the development of strategies to augment their immunogenicity while reducing their large-scale production costs. Therefore, finding efficient and economical alternatives for the production of epitopic vaccines could have an impact on researches using such immunogens. Herein, we report the recombinant production and immunological characterization of a short polypeptide which carries the three relevant epitopes contained in a C4V3 peptide. This polypeptide, named rC4V3, was efficiently produced in E. coli, yielding more than 75 mg per culture liter. No major difficulties were found in the recovery, refolding and purification of this peptide; the latter facilitated by C-terminal inclusion of a histidine tag. The immunogenicity of this protein was studied by administering it intramuscularly or intranasally to mice and it demonstrated to be a strong elicitor of anti-HIV antibodies at systemic and mucosal compartments. Remarkably, such responses were attained with rC4V3 even without the need of adjuvants. We can conclude that this protein might be a promising tool for studies using epitope-based vaccine designs.

UR - http://www.scopus.com/inward/record.url?scp=33745875334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745875334&partnerID=8YFLogxK

U2 - 10.1089/vim.2006.19.237

DO - 10.1089/vim.2006.19.237

M3 - Article

C2 - 16817766

AN - SCOPUS:33745875334

VL - 19

SP - 237

EP - 249

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 2

ER -